drugset
drugset / Trial / NCT01263236

A Study of LY2940094 in Major Depressive Disorder

NCT01263236 ↗

Phase 1 Completed 66 enrolled BlackThorn Therapeutics, Inc.
RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this study is to investigate the safety and tolerability of ascending single and multiple oral doses of LY2940094 in healthy male subjects.

Timeline

Start
2010-12
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2940094 Small molecule — Oral

Indications

major depressive disorder